實驗室
分機65122/65129

 
個人資料
 
研究成果
 
其他

 

 

張俊彥  國立成功大學醫學院 院長 / 國家衛生研究院癌症研究所 特聘研究員級主治醫師 (Jang-Yang Chang)

E-mail:z10208083@email.ncku.edu.tw

電話:06-2353535 分機5000 

傳真:06-2353660

 

學經歷

 

學歷

國防醫學院醫學士
     
  現職 國立成功大學醫學院 院長
    國家衛生研究院癌症研究所特聘研究員級主治醫師
     
  經歷 2013~ 國立成功大學醫學院 院長
    2008/09 國家衛生研究院癌症研究所特聘研究員
    2008/01 國家衛生研究院癌症研究所主任
    2007/08 成大醫院血液腫瘤科主治醫師
    2006/01~ 國家衛生研究院癌症研究所副主任
    2004/6-2008 Chairman, Safety and Data Monitoring committee, TCOG, Taiwan
    2004/04 國家衛生研究院癌症研究所調查員
    2003-2005 中華腫瘤學會常務理事
    2003/08 國防醫學院內科兼任教授
    2001 中華腫瘤學會董事會成員
    2000/9-2004/3 國家衛生研究院癌症研究所助理研究員
    1999 董事會成員Sino-American Cancer Foundatio,Taiwan
    1997 國家衛生研究院癌症研究所資深主治醫師
    1997 Chief, Hematology / Oncology, Cheng-Hsien Medical Center, Taiwan
    1997-2006 台大醫院腫瘤科兼任主治醫師
    1997-2001 中華腫瘤學會秘書長
    1994-2003/7 國防醫學院內科副教授
    1994-1996 骨髓移植學會董事會成員
    1993 三軍總醫院腫瘤科科長
    1991-1992 Attending physician, Medical Mission in Republic of Central Africa
    1989-1991 耶魯大學醫學院藥理學系訪問學者
    1987 三軍總醫院血液腫瘤科主治醫師
    1987-1989 Fellow of Medical Oncology Training Program, Institute of Biomedical Science, Academia Sinica, Taiwan
    1986-1987 三軍總醫院血液腫瘤科住院醫師
    1982-1986 Resident, 三軍總醫院
    1981-1982 Internship training, 三軍總醫院

 

專長/研究興趣

 

Medical Oncology, Cancer pharmacology and drug discovery

 

Dr. Chang's research interests focus on three fields; (1) study the mechanisms of drug resistance, especially camptothecins, and the relationship between CPT-resistance and DNA repair; (2) anti-cancer drug development, focusing on topoisomerase I and II and tubulin inhibitors; (3) regulation of DNA repair enzyme, MGMT.

 

 
  主要研究方向
 
  1. Development of anticancer drugs

  2. Study the mechanisms of anticancer drug resistance.
   
  研究項目:
 
臨床研究:
  1. A phase III study of postoperative adjuvant chemoradiotherapy for patients with stage III and IVb stomach cancer. (PI)

  2. A phase II study of gemcitabine and vinorelbine in cisplatin-resistant nasopharyngeal carcinoma patients. (co-PI)

  3. A phase I study of PI-88 in advanced malignancies. (co-PI)

  4. A phase I and PK study of thalidomide in hepatocellular carcinoma. (co-PI)

  5. A phase II study of weekly CPT-11 in recurrent NPC. (PI)

  6. A phase II study of weekly oxaliplatin plus HDFL in patients with advanced gastric cancer (co-PI)

  7. A phse II study of taxol, UFT and leucovorin in patients with advanced gastric cancer. (co-PI)

  8. A phase I/II study of docetaxel, cisplatin and HDFL in patients with advanced gastric cancer. (PI)

  9. A phase III study of thalidomide in patients with poor liver function hepatocellular carcinoma. (co-PI)

  10. Phase I and PK studies of PEP02 in patients with advanced malignancies. (PI)

  11. Phase I study of PEP02 with HDFL in patients with advanced malignancies. (co-PI)

  12. Phase I and PK study of biweekly PEP02 in patients with advanced colorectal cancer (PI).

 
基礎研究:
  1. Study the distribution of somatostatin receptor in human cancer tissue.

  2. Study the mechanism of CPT resistance in human nasopharyngeal cancer cells.

  3. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.

  4. Synthesis and structure-activity relationships of new AHMA derivatives as topoisomerase-II mediated antitumor agents.

  5. Study the indole derivatives as antitumor agents.

  6. Study the mechanims of action of BPR0Y007, a novel anticancer agent.

  7. Study the role of O6-MGMT in determining the cytotoxicty of topoisomerase I inhibitors.

  8. Transcriptional inhibition of O6MGMT gene of topoisomerase I inhibitors.

  9. Isolation the putative transporter responsible for resistance to topoisomerase I inhibitors in a vincristine-resistant cell line.

  10. Study the mechanism of action of a potential antitumor agent isolated from a herb medicine.

  11. Study the interaction of arsenic trioxide with antitumor agents.

  12. Study the interaction of new topoisomerase I inhibitor, DB67, with other antitumor agents.

  13. Study the pathway of BPR0Y007-induced apoptosis.

  14. Study on the regulation of DNA repair enzyme, MGMT, in human cancer cells.

  15. Study on the development of anti-tubulin compounds
 

榮譽獎項

 
  2010 Outstanding Poster Award, The 15th Annual Taiwan Joint Cancer Conference, 2010
  2008 Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference
  2007 Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference
  2006 Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference
  2005 徐千田防癌研究基金癌症傑出研究獎 (基礎組)
  2005 Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference
  2004 Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference
  2003 Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference
  2001 Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference